Abstract OT3-08-01: A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress)Dejan Juric, Funda Meric‐Bernstam, Muralidhar Beeram et al.|Cancer Research|2023Cited by 9